BACKGROUND Targeted therapies have markedly changed the treatment of cancer over
the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a …

Tissue biopsy is the standard diagnostic procedure for cancers and also provides a material
for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy …

The notion of utilizing cell-free DNA (cfDNA) 8 in the circulation as a surrogate biomarker is
not a novel concept. Mandel and Metais identified the presence of cfDNA in the blood of …

Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

Cancer is a common cause of death worldwide. Despite significant advances in cancer
treatments, the morbidity and mortality are still enormous. Tumor heterogeneity, especially …

Simple Summary An important advance in the diagnostic and surveillance toolbox for
oncologists is circulating tumor DNA (ctDNA). This technology can detect microscopic levels …

The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might
revolutionize cancer care with respect to early detection, identification of minimal residual …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Cancer cells shed naked DNA molecules into the circulation. This circulating tumor DNA
(ctDNA) has become the predominant analyte for liquid biopsies to understand the …